The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram
Kevin J Friesen, Shawn C BugdenFaculty of Health Sciences, College of Pharmacy, University of Manitoba, Winnipeg, MB, CanadaBackground: Citalopram is the most commonly prescribed antidepressant in Canada. Concerns have been raised about its cardiac safety, and a dose-dependent prolongation of the QT...
Main Authors: | Friesen KJ, Bugden SC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-08-01
|
Series: | Drug, Healthcare and Patient Safety |
Online Access: | http://www.dovepress.com/the-effectiveness-and-limitations-of-regulatory-warnings-for-the-safe--peer-reviewed-article-DHPS |
Similar Items
-
Voluntary warnings and the limits of good prescribing behavior: the case for de-adoption of meperidine
by: Friesen KJ, et al.
Published: (2015-12-01) -
Diplopia; an Adverse Effect of Citalopram
by: Seyed Hamzeh Hosseini, et al.
Published: (2019-09-01) -
Safe and effective prescribing with dyslexia
by: Sebastian C. K. Shaw, et al.
Published: (2019-07-01) -
The use of citalopram for the treatment of cataplexy
by: Hassana de Almeida Fonseca, et al.
Published: (2014-03-01) -
Effects of Citalopram on Sutural and Calvarial Cell Processes.
by: Emily Durham, et al.
Published: (2015-01-01)